Breckenridge Pharmaceutical, Inc. Announces Approval of Mefenamic Acid Capsules, USP 250mg

BOCA RATON, Fla., Oct. 14, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces the immediate launch of Mefenamic Acid 250mg Capsules.  The U.S. Food and Drug Administration previously granted final approval for the Abbreviated New Drug Application (ANDA) for this product.  This product is one of five approved Breckenridge ANDA products secured from the September 2013 acquisition of certain Cypress Pharmaceutical, Inc. product assets.

Breckenridge's Mefenamic Acid Capsules are AB rated to Ponstel® a generic drug marketed by Shionogi Pharma, Inc., a $10.3 million dollar generic based on August 2014 IMS Health sales data.

Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the relief of mild to moderate pain in patients greater than or equal to 14 years of age, when therapy will not exceed one week (7 days). It is also indicated for the treatment of primary dysmenorrhea.

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories.  The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide.  Breckenridge markets in excess of fifty (50) products in a variety of dosage forms and therapeutic categories.  www.bpirx.com

Ponstel® is a registered trademark of Shinogi Pharma, Inc. or its affiliates.

SOURCE Breckenridge Pharmaceutical, Inc.